Despite the fluctuations in the AstraZeneca vaccine, Health Canada announced Thursday that the unpopular vaccine will continue to recommend it to all segments of the population.
“Based on all current international data to date, Health Canada continues to see that the benefits of AstraZeneca and COVISHIELD vaccines in terms of protection against COVID-19 outweigh the risks,” the ministry said in a press release.
On Monday, the National Advisory Committee on Immunization (NACI) changed its dosage by advising against the use of this vaccine in children under 55. Quebec immediately adopted the recommendation, but Health Canada did not change its mind.
On the same day, Health Canada announced that AstraZeneca and COVISHIELD vaccine manufacturers, produced at the Serum Institute in India, will be required to provide more detailed scientific information.
It was said Thursday: “Health Canada will take this information into account as part of its ongoing assessment process related to this safety issue.”
So far, no case of fatal side effects has been identified in Canada. Cases of blood clots are still extremely rare in the world. More than 300,000 Canadians have received doses of the AstraZeneca vaccine to date.
AstraZeneca quietly changed the name of the vaccine to Vaxzevria, a change verified on March 25th by the European Medicines Agency (EMA).
“Evil thinker. Music scholar. Hipster-friendly communicator. Bacon geek. Amateur internet enthusiast. Introvert.”